Pivotal-Point Tracking Supernus Pharmaceuticals (SUPN): Price Target Explosion After Piper Sandler Upgrade – Parkinson's Drug Onapgo as a New Revenue Star!
Reading Time: 1 minute
Supernus Pharmaceuticals is a biopharmaceutical company based in the USA that focuses on the development and commercialization of products for the treatment of central nervous system (CNS) disorders, including ADHD, Parkinson's disease, and epilepsy. The company benefits from strong growth in its key products and an expanded market position through acquisitions, thereby meeting the ongoing high demand for innovative neurological therapies. The significant price jump on October 9, 2025, was directly attributable to an upgrade and a substantial increase...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
